Bollate, ITALY, Nov. 13, 2018 -- Solvay, a leading global supplier of specialty polymers, has broadened its portfolio of high-performance filaments for premium additive manufacturing (AM) applications with the introduction of three medical grade products for use in the healthcare industry.
Solvay has broadened its portfolio of high-performance filaments for premium additive manufacturing (AM) applications with the introduction of three medical grade products for use in the healthcare industry. Photo: Solvay.
A neat KetaSpire® polyetheretherketone (PEEK) AM filament (NT1 HC) and a 10-percent carbon fibre reinforced KetaSpire® PEEK AM filament (CF10 HC), together with a neat Radel® polyphenylsulfone (PPSU) AM filament (NT1 HC) are Solvay’s first medical grade AM filaments for limited contact applications (<24hr bodily fluid/tissue contact). All three grades are immediately available in Europe and North America at Solvay’s e-commerce platform www.solvayamshop.com.
“The healthcare industry is quickly emerging as a leading market to benefit from AM technology which makes customized parts for single use or low volumes possible,” says Christophe Schramm, Additive Manufacturing business manager at Solvay’s Specialty Polymers global business unit (GBU). “However, there is still a very limited choice of high-performance filaments that meet the stringent regulatory requirements in healthcare and this is the gap we want to close with our new selection of medical grade products.”
Solvay’s KetaSpire® PEEK AM filaments are designed to allow excellent fusion of printed layers, enable high part density and deliver exceptional part strength, including along the z-axis. Radel® PPSU AM filaments also provide excellent fusion of printed layers in addition to transparency, high elongation and toughness.
“These new medical grade AM filaments emphasize Solvay’s continuing, pro-active initiatives to support our customers. The filaments can be used for a range of healthcare applications such as patient-specific cutting guides for surgery and for complex components in single-use and reusable medical devices,” said Jeff Hrivnak, global business manager for Healthcare at Solvay’s Specialty Polymers GBU.
® KetaSpire and Radel are registered trademarks of Solvay.
Solvay is an advanced materials and specialty chemicals company, committed to developing chemistry that addresses key societal challenges. Solvay innovates and partners with customers worldwide in many diverse end markets. Its products are used in planes, cars, batteries, smart and medical devices, as well as in mineral and oil and gas extraction, enhancing efficiency and sustainability. Its lightweighting materials promote cleaner mobility, its formulations optimize the use of resources and its performance chemicals improve air and water quality. Solvay is headquartered in Brussels with around 26,800 employees in 61 countries. Net sales were €10.1 billion in 2017, with 90% from activities where Solvay ranks among the world’s top 3 leaders, resulting in an EBITDA margin of 22%. Solvay SA ( SOLB.BE) is listed on Euronext Brussels and Paris (Bloomberg: SOLB.BB - Reuters: SOLB.BR) and in the United States its shares (SOLVY) are traded through a level-1 ADR program. Financial figures take into account the announced divestment of Polyamides.
Solvay Specialty Polymers manufactures over 1500 products across 35 brands of high-performance polymers – fluoropolymers, fluoroelastomers, fluorinated fluids, semi-aromatic polyamides, sulfone polymers, ultra-high performance aromatic polymers, and high-barrier polymers – for use in Aerospace, Alternative Energy, Automotive, Healthcare, Membranes, Oil and Gas, Packaging, Plumbing, Semiconductors, Wire & Cable, and other industries. Learn more at
www.solvayspecialtypolymers.com.
Contacts:
Enrico Zanini
Solvay Specialty Polymers
+39 02 2909 2127
Email Contact
Alan Flower
Industrial Media Relations
+32 474 117 091
Email Contact
Marla Witbrod
Solvay Specialty Polymers
+1 770 772 8451
Email Contact
Dan McCarthy
AH&M Marketing Communications
+1 413 448 2260 Ext. 200
Email Contact
